Optiscan Board Changes
Optiscan Imaging Limited wishes to announce the following appointments to the board:
Alan Hoffman has more than 20 years’ experience in executive management roles in organisations such as Shell Australia, the Wesfarmers Group and the Coventry Group. His core strengths are improving business performance, influencing and managing change, and expertly motivating and guiding teams towards the attainment of goals. Commercially astute and strategically focused, Alan’s leadership will drive performance improvement of Optiscan as it moves into delivering on its potential.
Peter Francis is a Partner of FAL Lawyers, a firm of commercial and technology lawyers with offices in Melbourne, Australia. He is one of Australia’s pre-eminent lawyers on technology commercialisation and is considered to be a ‘true expert with years of experience’, ‘particularly esteemed in non-contentious circles for his dexterous handling of commercialisation work for research organisations and technology developers’ (IAM Licensing 250, 2011/2012, IAM Patent 1000, 2012). Peter is Chairman of Benitec Biopharma Ltd (ASX:BLT) and holds a number of other non-executive director roles.
Dr Ian Griffiths
Dr Ian Griffiths is currently CEO of Wound Management Innovation CRC and has previously held the following positions; CEO of AorTech Biomaterials Pty Ltd, COO of AorTech International plc, CEO of PolyNovo Pty Ltd and CEO of Novoskin Pty Ltd. Ian has worked for more than 19 years in commercialising innovative medical devices. In addition, Ian has served on a number of public and private company boards. Dr Griffiths has an honours degree, a business degree, and a PhD from the University of Manchester with his thesis based on instrumentation physics and polymer chemistry. Dr Griffiths has been a guest speaker at numerous public events, conferences and investment forums and has a distinguished academic publication list. He has an extensive background in business development, licensing & acquisitions, medical technology commercialisation, capital raising and critical stakeholder management.
Additionally, the current director remains on the board of Optiscan Imaging Limited.
Ian Mann has 20 years experience as a private company director in industries including textiles, garments, investments, foodstuffs & construction materials. One entity of which Ian is a Director became a Substantial Shareholder in Optiscan in August 2011. Ian joined the board in December 2015 bringing financial support and vision for the path towards profitability. Ian has been pivotal in ensuring governance and commercial focus since joining in December and remains an invaluable member of the new look board.
Board Changes – Resignations
Optiscan wishes to announce the following resignation from the board
Mr Delaney will remain as an employee of the company. The board wishes to thank Peter Delaney for his contributions as a board member of Optiscan Imaging Limited since 1997 and are pleased with Peter’s decision to remain as an executive of the company.
Optiscan is an Australian company that has developed and patented miniaturised confocal microscopes, and is now a global leader in the development and application of microscopic imaging technologies for medical markets.
For further information please contact:
M: +61 408 968 013
P: (61) 3 9538 3333